Business
PetLife Pharmaceutical Taps National Public Relations Firm to Help Bring to Market Cancer Treatment Originally Developed by Cuba
PetLife Pharmaceutical Taps National Public Relations Firm to Help Bring to Market Cancer Treatment Originally Developed by Cuba.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n \n PetLife \n Pharmaceuticals, Inc. (OTCQB:PTLF) (the \"Company\"), a developer of a \n new generation of high potency veterinary cancer medications and \n nutraceuticals for pets, announced today that it has retained Gregory \n FCA Communications, Inc., one of the \n nation’s largest public relations agencies, to help bring to market a \n breakthrough cancer treatment for pets produced from the venom of the \n blue scorpion.\n \n \n Venom from the blue scorpion, which is native only to Haiti, Cuba, the \n Dominican Republic, and Venezuela, has been used for more than 20 years \n in Cuba to treat cancer patients. Blue scorpion venom is one of the most \n expensive liquids in the world.\n \n \n PetLife Pharmaceuticals is embarking on a series of clinical trials for \n its use in pets here in the U.S. The announcement comes on the heels of \n PetLife Pharmaceuticals’ appointment of Dr. R. Geoffrey Broderick as \n Chairman of Product Development. As one of the world’s most famous \n veterinarians, Dr. Broderick is considered the father of the natural pet \n food industry and who has been working for the past 50 years to reduce \n and prevent cancer in dogs and cats.\n \n \n “Nearly 13 million pets receive a cancer diagnosis each year, and for \n many it’s a death sentence,” begins Dr. Broderick. “Nearly 50 percent of \n pets age 10 and over will die from cancer. Current treatments—including \n surgery and chemotherapy—are heinously expensive, barbaric, and riddled \n with side effects. PetLife Pharmaceuticals is the first organization in \n the world to investigate the use of scorpion venom as a non-toxic \n treatment for cancer, which has the promise of saving millions of pets, \n while improving the quality of life for both pets and their owners.”\n \n \n “PetLife Pharmaceuticals’ commitment to saving pets lives through this \n novel therapy is filling a desperately needed unmet medical need in \n veterinary care,” says Greg Matusky, president and founder of Gregory \n FCA. “It’s critically important that this drug becomes available to pets \n and their owners here in the U.S., considering the opening of relations \n with Cuba and recent acceptance of many medical discoveries made there.”\n \n \n For instance, last fall, Roswell Par...